KR102783648B1 - (s, e)-4-(디메틸아미노)-n-(3-(4-(2-히드록시-1-페닐에틸아미노)-6-페닐퓨로[2,3-d]피리미딘-5-일)페닐)부트-2-엔아미드 유리 염기의 결정형 - Google Patents

(s, e)-4-(디메틸아미노)-n-(3-(4-(2-히드록시-1-페닐에틸아미노)-6-페닐퓨로[2,3-d]피리미딘-5-일)페닐)부트-2-엔아미드 유리 염기의 결정형 Download PDF

Info

Publication number
KR102783648B1
KR102783648B1 KR1020237023847A KR20237023847A KR102783648B1 KR 102783648 B1 KR102783648 B1 KR 102783648B1 KR 1020237023847 A KR1020237023847 A KR 1020237023847A KR 20237023847 A KR20237023847 A KR 20237023847A KR 102783648 B1 KR102783648 B1 KR 102783648B1
Authority
KR
South Korea
Prior art keywords
crystalline form
abt
free base
cancer
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237023847A
Other languages
English (en)
Korean (ko)
Other versions
KR20230118963A (ko
Inventor
투-안 쉬
싱-방 셰
수-밍 장
Original Assignee
시, 추안
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시, 추안 filed Critical 시, 추안
Publication of KR20230118963A publication Critical patent/KR20230118963A/ko
Application granted granted Critical
Publication of KR102783648B1 publication Critical patent/KR102783648B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020237023847A 2021-07-06 2022-07-06 (s, e)-4-(디메틸아미노)-n-(3-(4-(2-히드록시-1-페닐에틸아미노)-6-페닐퓨로[2,3-d]피리미딘-5-일)페닐)부트-2-엔아미드 유리 염기의 결정형 Active KR102783648B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163218504P 2021-07-06 2021-07-06
US63/218,504 2021-07-06
PCT/US2022/036260 WO2023283269A1 (en) 2021-07-06 2022-07-06 Crystalline forms of (s, e)-4-(dimethylamino)-n-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base

Publications (2)

Publication Number Publication Date
KR20230118963A KR20230118963A (ko) 2023-08-14
KR102783648B1 true KR102783648B1 (ko) 2025-03-18

Family

ID=84802010

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237023847A Active KR102783648B1 (ko) 2021-07-06 2022-07-06 (s, e)-4-(디메틸아미노)-n-(3-(4-(2-히드록시-1-페닐에틸아미노)-6-페닐퓨로[2,3-d]피리미딘-5-일)페닐)부트-2-엔아미드 유리 염기의 결정형

Country Status (12)

Country Link
US (2) US12240858B2 (enExample)
EP (1) EP4330259A4 (enExample)
JP (1) JP7565118B2 (enExample)
KR (1) KR102783648B1 (enExample)
CN (1) CN116916922B (enExample)
AU (1) AU2022307875B2 (enExample)
BR (1) BR112023024853A2 (enExample)
CA (1) CA3217088A1 (enExample)
IL (1) IL308946B2 (enExample)
MX (1) MX2023013093A (enExample)
TW (1) TWI809967B (enExample)
WO (1) WO2023283269A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI906763B (zh) * 2024-02-05 2025-12-01 財團法人國家衛生研究院 表皮生長因子受體抑制劑

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8507502B2 (en) * 2008-11-10 2013-08-13 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
KR101301533B1 (ko) * 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체

Also Published As

Publication number Publication date
TW202309041A (zh) 2023-03-01
JP2024514995A (ja) 2024-04-04
US12240858B2 (en) 2025-03-04
IL308946A (en) 2024-01-01
IL308946B2 (en) 2026-01-01
CA3217088A1 (en) 2023-01-12
BR112023024853A2 (pt) 2024-02-15
CN116916922A (zh) 2023-10-20
TWI809967B (zh) 2023-07-21
WO2023283269A1 (en) 2023-01-12
AU2022307875A1 (en) 2023-11-02
CN116916922B (zh) 2026-01-02
AU2022307875B2 (en) 2024-08-01
US20230021909A1 (en) 2023-01-26
EP4330259A4 (en) 2024-10-09
KR20230118963A (ko) 2023-08-14
EP4330259A1 (en) 2024-03-06
JP7565118B2 (ja) 2024-10-10
IL308946B1 (en) 2025-09-01
US20240368175A1 (en) 2024-11-07
MX2023013093A (es) 2024-04-09

Similar Documents

Publication Publication Date Title
JP7383652B2 (ja) Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
JP4456079B2 (ja) ｛６，７−ビス（２−メトキシ−エトキシ）−キナゾリン−４−イル｝−（３ｅ）の多形体
TW202311259A (zh) 化合物i的新形式及其應用
US20230167128A1 (en) Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
CN106167485A (zh) 苯甲酰胺类，含有苯甲酰胺类的组合物以及苯甲酰胺类的制备方法
EP3927696B1 (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
EP3612527B1 (en) Heterocyclic compounds useful as modulators of acetylcholine receptors
JP2018039807A (ja) 結晶形態の（Ｓ）−４−アミノ−Ｎ−（１−（４−クロロフェニル）−３−ヒドロキシプロピル）−１−（７Ｈ−ピロロ［２，３−ｄ］−ピリミジン−４−イル）ピペリジン−４−カルボキサミド
KR102783648B1 (ko) (s, e)-4-(디메틸아미노)-n-(3-(4-(2-히드록시-1-페닐에틸아미노)-6-페닐퓨로[2,3-d]피리미딘-5-일)페닐)부트-2-엔아미드 유리 염기의 결정형
CN114630819A (zh) 用于预防或治疗癌症的苯甲酰胺衍生物、其制备方法以及包含其作为活性成分的药物组合物
US9120815B2 (en) Solid state forms of macrocyclic kinase inhibitors
RU2851691C2 (ru) Кристаллические формы свободного основания (S,E)-4-(диметиламино)-N-(3-(4-(2-гидрокси-1-фенилэтиламино)-6-фенилфуро[2,3-d]пиримидин-5-ил)фенил)бут-2-енамида
KR20160075824A (ko) 2-(4-(2-(1-이소프로필-3-메틸-1H-1,2,4-트라이아졸-5-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)-1H-피라졸-1-일)-2-메틸프로판아미드의 다형체, 이의 제조 방법 및 이의 약학적 용도
HK40094095A (zh) (s，e)-4-(二甲胺基)-n-(3-(4-(2-羟基-1-苯乙胺基)-6-苯基呋喃并[2，3-d]嘧啶-5-基)苯基)丁-2-烯醯胺游离硷的晶型
EP3750894B1 (en) Urea-substituted aromatic ring-linked dioxazoline compound, preparation method therefor, and uses thereof
TW202517624A (zh) Mek免疫腫瘤抑制劑醫藥組合物
KR20250098089A (ko) 퀴나졸린 유도체 화합물의 신규한 염 및 이의 제조방법
US20210340142A1 (en) Salt form and crystal form of novel azatricyclic compound and use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230713

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20240724

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240802

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241120

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20250218

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20250224

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250314

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250314

End annual number: 3

Start annual number: 1

PG1601 Publication of registration